Navigation Links
Anesiva Announces Expansion of Zingo Agreement in Europe
Date:5/1/2008

SOUTH SAN FRANCISCO, Calif., May 1 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced the expansion of the company's license and distribution agreement for Zingo(TM) with Sigma-Tau SpA to include additional European countries. Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system is approved in the United States to provide topical local analgesia prior to peripheral IV insertions or blood draws in children three to 18 years of age.

Under the expanded agreement, Sigma-Tau now has exclusive rights to market and distribute Zingo in all major European markets, excluding the British Isles and the Scandinavian countries. Terms of the expanded agreement include additional upfront payments to Anesiva and transfer price, as well as a milestone payment.

"The expansion of this agreement reflects enthusiasm about the global potential for Zingo to provide quick-onset, needle-free analgesia prior to peripheral venous access procedures in children," said Samantha R. Miller, Anesiva's vice president, business development. "Since the initial agreement was signed in February 2008, Sigma-Tau has made significant progress in defining the regulatory pathway to support commercialization of Zingo in the licensed countries."

About Zingo(TM)

Zingo(TM) is an easy-to-administer, single-use, needle-free system that delivers sterile lidocaine powder to provide topical, local anesthesia to reduce the pain associated with peripheral IV insertions or blood draws. Zingo's rapid onset of action allows intravenous line placement or venipuncture to begin one to three minutes after administration. Zingo is approved in the U.S. to reduce the pain associated with peripheral IV insertions or blood draws in children three to 18 years of age. In clinical trials, the most common adverse events with Zingo were redness (erythema), red dots (petechiae) and swelling (edema). In March 2008, Anesiva submitted a supplemental new drug application (sNDA) to expand the label indication for Zingo to include adults, based on a positive Phase 3 trial in nearly 700 patients.

About Anesiva and its Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA, USA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, whether Anesiva is able to manufacture its products on commercially reasonable terms, and the degree to which Zingo gains market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's annual report on Form 10-K for the year ended December 31, 2007.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Announces New Zingo Marketing and Distribution Agreement
2. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
3. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
4. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
5. Anesiva Appoints Daniel Janney to Board of Directors
6. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
7. Anesiva Announces Completion of Common Stock Offering
8. Anesiva Raises $45 Million in Common Stock Offering
9. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
10. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
11. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... England , December 8, 2016 ... has expanded its customisable SureSeqâ„¢ NGS panel range with the ... allowing fast and cost-effective study of variants in familial hypercholesterolemia ... number variation (CNV) detection on a single small panel and ... hotspot content. This includes all exons for LDLR , ...
(Date:12/8/2016)... ... December 08, 2016 , ... This CAST literature review and report looks at ... focus on the economic effects in countries that are major global commodity exporters and ... the resultant risk of low level presence (LLP) puts large volumes of trade worth ...
(Date:12/8/2016)... South Korea , Dec. 8, 2016 ... a $21 billion KRW (US $18.9M) Series A financing. ... Kolon Investment, G.N. Tech Venture and SNU Bio Angel. ... Eutilex to 30.5 billion KRW (US $27.7M) since its ... help Eutilex to bolster the development and commercialization of ...
(Date:12/7/2016)... ... December 07, 2016 , ... Huffman Engineering, Inc. , ... Wonderware Certified System Integrator Partner. Huffman Engineering is the only Nebraska-based company ... System Integrator Partner certification gives customers confidence that our engineers are fully trained ...
Breaking Biology Technology:
(Date:11/17/2016)... announces that it has just released a new white paper authored by Zettar that ... speed data transfer storage solutions. Photo - http://photos.prnewswire.com/prnh/20161116/440463 ... ... ... Setting up a high performance computing or HPC system can be a ...
(Date:11/15/2016)... 15, 2016 Research and Markets has announced ... 2021" report to their offering. ... ... by 2021 from USD 6.21 Billion in 2016, growing at a ... of the bioinformatics market is driven by the growing demand for ...
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
Breaking Biology News(10 mins):